RxDoctor Payments Data

Roxie Chisholm

Family · Columbia, SCNPI 1932502572

Payments from drug & device makers

$1,249in general payments, 2019–2025

Across 71 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$197
  • Lilly USA, LLC$166
  • AbbVie$148
  • Pfizer$109
  • AstraZeneca$106
  • Abbott$102
  • plus $420 from 13 others

What the payments were for

  • Food & beverage$1,249100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,249 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$121,406
Medicare patients
299
Services billed
2,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$134,284
TrulicityDulaglutide38$56,153
EliquisApixaban37$43,245
JardianceEmpagliflozin37$41,857
MounjaroTirzepatide25$40,581
JanuviaSitagliptin Phosphate34$36,493
Repatha SureclickEvolocumab20$29,784
LinzessLinaclotide14$18,611
FarxigaDapagliflozin Propanediol14$17,653
Janumet XrSitagliptin Phos/Metformin Hcl11$8,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,629
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid14$3,344
Rosuvastatin Calcium187$3,102
Atorvastatin Calcium241$3,076
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$134,28478 claims
Lilly USA, LLCTrulicity, Mounjaro$166$96,73363 claims
PfizerEliquis$109$43,24537 claims
Boehringer IngelheimJardiance$61$41,85737 claims
AbbVieLinzess$148$18,61114 claims
AstraZenecaFarxiga$106$17,65314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →